Candel Therapeutics Appoints Three New Members to its Board of Directors
August 01, 2022 08:00 ET
|
Candel Therapeutics
Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health companyJoseph Papa, Chief Executive Officer of Bausch + Lomb...
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
May 26, 2022 17:30 ET
|
Candel Therapeutics
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of...
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
May 18, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 12, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 16:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
March 29, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
March 02, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
March 01, 2022 08:00 ET
|
Candel Therapeutics
Additional capital extends cash runway into Q4 of 2023 NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the “Company” or “Candel”), a late clinical stage...
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
February 03, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics to Present at Two Upcoming Investor Conferences
January 05, 2022 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...